How did we get here? Until now, vaccines for all children under age 12 had been available under emergency use authorization ...

Moderna may be facing regulatory uncertainty in the US for its vaccine pipeline, but at least its clinical data is hitting the right notes.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

REUTERS — The U.S. Centers for Disease Control and Prevention has ended its emergency response for H5N1 avian flu, owing to a decline in animal infections and no reports of human cases since February.

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...

Detailed price information for Canopy Growth Corp (CGC-Q) from The Globe and Mail including charting and trades.

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="334655" class="cbxwpbkmarktrig ...

COVID-19 cases are rising in half of U.S. states. What to know about COVID trends and the new Stratus and Nimbus variants.